ClinicalTrials.gg
Status unknownNCT05290220Updated May 3, 2022

HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma

A Phase 2 interventional study of HLX07 and HLX10 in Advanced Hepatocellular Carcinoma, sponsored by Shanghai Henlius Biotech. Status unknown. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-05-03.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is conducted in patients with advanced hepatocellular carcinoma (HCC). This study includes three arms: A, B, and C. Arm A will receive HLX07 combination therapy with HLX10 and HLX04 as first line treatment. Arm B will receive HLX07 combination therapy with lenvatinib as second line treatment. Arm C will receive HLX07 monotherapy as third-line or above treatment. All of eligible patients will receive study drug treatment until loss of clinical benefit, unacceptable toxicity, death, withdrawal of informed consent (whichever occurs first, HLX10 treatment up to 2 years).

02

Conditions studied

  • Advanced Hepatocellular Carcinoma
03

In context

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

This study's planned enrollment of 60 is above the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.

Browse Carcinoma, Hepatocellular studies →

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects who meet all of the following criteria are allowed to be enrolled into this study:

  1. Volunteer to participate in this clinical study; completely understand and know this study as well as sign the form (ICF); be willing to follow and be able to complete all study procedures.
  2. Age ≥ 18 years and ≤ 75 years when ICF is signed.
  3. Histopathologically or confirmed diagnosis of advanced hepatocellular carcinoma (HCC), Or the clinical diagnosis meets the american association for the study of liver diseases (AASLD) diagnostic criteria for HCC.
  4. prior therapy: Arm A: Never received systemic anti-tumor drug therapy before. Arm B: Patient has a or intolerance to, or has failed treatment with 1-line systemic anti-tumor therapy ( /L1 -based combination therapies). Arm C: Previously received second or greater . (Including: 1. PD-1/L1-based therapy 2. Lenvatinib or Sorafenib).
  5. According to the curative effect evaluation criteria in solid tumors () v1.1, assessed by the investigator with at least one . Measurable target lesions cannot be selected from the site of previous radiotherapy.

    (lesions located in the usual radiation area, if confirm progress, can also be selected as the target lesion).

  6. liver function rating within 7 days before the first administration of the study drug : grade A and good grade B (≤ 7 points).
  7. Arm B,C: The end of previous systematic treatment() must be ≥ 2 weeks before the first administration of the study drug, and the treatment-related AE should be restored to the level of NCI - ≤ 1 (except hair loss).
  8. The patient with HCC has liver surgery or local treatment (hepatic artery embolization, TACE, hepatic artery infusion, radiofrequency ablation, cryoablation or percutaneous ethanol injection) , Arm A and B : treatment was received ≥ 4 weeks prior to the first administration of this study. Arm C: treatment was received ≥ 2 weeks prior to the first administration of this study; The palliative radiotherapy for bone was received ≥ 2 weeks prior to the first administration of this study; The diagnostic liver puncturewas received ≥ 1weeks prior to the first administration of this study. AEs related to previous local therapy should be recovered to the level of NCI -CTCAE ≤ 1.
  9. The physical performance score within 7 days before the first administration of the study drug was 0 or 1.
  10. Expected survival ≥ 12 weeks.
  11. If (+) or HBcAb (+), HBV-DNA must be\<2500 copy/ml or ≤ 500 IU/mL or \< to be included in the group, and those with elevated HBV-DNA must agree to receive nucleoside anti-hepatitis b virus treatment. Subjects with negative antibody (-) or HCV-RNA were admitted. If HCV-RNA is positive, must agree to receive standard of anti-virus treatment, and subjects must have and AST ≤ 3×ULN to be enrolled. Subjects with co-infection of hepatitis b and c should be excluded.
  12. The functions of the vital organs meet the following requirements (no blood transfusion, albumin, colony-stimulating factor, or raising drugs are allowed within 14 days before the first use of the study drugs); (ANC) ≥1.5×109/L platelet≥ 100×109/L; ≥ 90g/ L; Serum albumin≥ 30g/L; Total ≤ 1.5 ULN, ALT, AST≤ 5 ULN(exclude the HCV-RNA is positive patients);Serum creatinine≤1.5 ULN or > 50 mL/min (Cockcroft-Gault formula);, INR and PT ≤1.5 ULN; Qualitative analysis of proteinuria≤1+; If ≥2+, 24-hour urine protein test is required, and the subject must have\<1g to be enrolled.
  13. For fertile female subjects, the serum pregnancy test must be negative within 7 days before the first dose.Subject agrees to use effective .

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria are not allowed to be enrolled in this study:

  1. Hepatobiliary duct cell carcinoma, mixed cell carcinoma, or fibroblastic layer cell carcinoma are known.
  2. Hepatic encephalopathy within 6 months before the first administration of the study drug.
  3. According to the images, portal vein invasion, inferior vena cava or cardiac involvement of HCC main portal branch (Vp4) were present. Patients with cancer thrombus in main portal vein but smooth blood flow in contralateral branch can be enrolled.
  4. Other active within 3 years prior to the first administration of the study drug.Curable localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder carcinoma, carcinoma in situ of the prostate, cervical carcinoma in situ, and carcinoma in situ of the breast, can be included in the group.
  5. People who are ready to undergo or have received organ or bone marrow transplants.
  6. After appropriate intervention, uncontrollable pleural effusion, pericardial effusion or ascites still need to be drained frequently (once a month or more frequently).
  7. Symptomatic brain or meningeal (unless the patient has been on > treatment for 3 months, has no evidence of progress on imaging within 4 weeks prior to initial administration, and tumor-related clinical symptoms are stable).
  8. Cerebrovascular accident, Pulmonary embolism, deep vein thrombosis or any other serious thromboembolism, myocardial infarction, unstable angina pectoris and poorly controlled arrhythmia occurred within half a year (including ≥ 450 ms for men and ≥ 470 ms for women) (QTc interval was calculated by Fridericia formula).
  9. According to the (NYHA) standard levels Ⅲ or Ⅳ cardiac insufficiency or heart colour to exceed examination: (left ventricular ejection fraction) \< 50%.
  10. (HIV) infection.
  11. Active tuberculosis.Patients with previous and current cases of interstitial pneumonia, pneumoconiosis, radioactive pneumonia, drug-related pneumonia, and severe impairment of lung function that may interfere with the detection and management of suspected drug-related lung toxicity.
  12. Within 14 days prior to the first administration of the study drug, any active infection requiring systematic anti-infective treatment occurs.
  13. Major surgery was performed within 28 days prior to the first administration of the study drug. Major surgery in this study was defined as the minimum recovery time of 3 weeks after surgery before the surgery treated in this study could be performed.
  14. Within 14 days prior to the first administration of the study drug, participating in other clinical studies.
  15. Subjects requiring systemic treatment with (> 10 mg/ day or equivalent dose of prednisone) or other within 14 days prior to or during the study.In the absence of active disease, the inhalation or topical use of steroids, or adrenal hormone replacement at doses less than 10 mg/ day of prednisone efficacy, is permitted.
  16. Patients who have previously received systemic anti-EGFR monoclonal antibody therapy.
  17. History of severe to any monoclonal antibody or study drug .
  18. Pregnant or lactating women.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Arm A: As first-line therapy

    HLX07 1500 mg + HLX10 300 mg + HLX04 15mg/kg iv q3w

    Drug: HLX07 · Drug: HLX10 · Drug: HLX04

  • Experimental
    Arm B: As second-line therapy

    HLX07 1500 mg iv Q3w + Lenvatinib 12 mg (BW≥60 kg) or 8 mg (BW \<60 kg) po qd

    Drug: HLX07 · Drug: lenvatinib

  • Experimental
    Arm C:As third-line or above therapy

    HLX07 1500 mg iv Q3w

    Drug: HLX07

Interventions

06

What researchers measure

Primary outcomes

  1. ORR

    Objective response rate by INV assessment per RECIST

    Time frame: up to 2 years

  2. PFS

    Progression-free survival by INV assessment per RECIST

    Time frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years

Secondary outcomes

  1. OS

    Overall survival

    Time frame: from the date of first dose unitl the date of death from any cause, assessed up to 2 years

  2. DOR

    Duration of response

    Time frame: from the date when CR or PR (whichever recorded earlier) is firstly achieved until the date when disease progression or death is firstly recorded (whichever occurs earlier),assessed up to 2 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2022; primary completion for Dec 2023, 16 months later.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's planned 16 months is below that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2022
First posted
Mar 22, 2022
StartEst.
Aug 1, 2022
Primary completionEst.
Dec 15, 2023
CompletionEst.
Dec 15, 2024
Last update
May 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05290220
Responsible party
Sponsor
First posted
Mar 22, 2022
Start date
Aug 1, 2022 (estimated)
Primary completion
Dec 15, 2023 (estimated)
Completion
Dec 15, 2024 (estimated)
Last update
May 3, 2022

Study contacts

Zhenggang Ren
Contact
ren.zhenggang@zs-hospital.sh.cn
13681971302

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HLX07

Start the discussion